St Andrews-based impact investment firm Eos Advisory has led a £7.8 million series A round into Naturbeads, a climate tech startup addressing microplastic pollution. Founded in 2018 as a spinout from the University of Bath, Naturbeads is now scaling its innovative plant-based microsphere techn
Eos Advisory
Nami Surgical, a Scottish company innovating robotic-assisted surgery, has received a total of £3.2 million of investment and grant funding to revolutionise the field with its ultrasonic platform. St Andrews-based impact investment firm Eos Advisory (Eos) led the seed £2.5m round alongsi
St Andrews-based investment firm Eos Advisory has led a £2.5 million investment into Neupulse, a start-up developing the world's first wearable device aimed at tackling Tourettes Syndrome (TS) and other tic disorders towards commercialisation. Neupulse’s recently finalised working protot
Pathways Forward has launched its Pledge initiative with leading organisations committing to actionable steps aligned with the principles set out in the Pathways report, with their performance measured over a 12-month period. AccelerateHER, CivTech, CodeBase, Deloitte, Eos Advisory, Scottish EDGE, a
Edinburgh-based cancer therapeutics development specialist Cumulus Oncology has successfully secured a £9 million funding package, including a significant contribution of £6m from the Scottish National Investment Bank. The funds are earmarked to bolster Cumulus's portfolio of companies d
St Andrews-based impact investment firm Eos Advisory LLP has announced a series of executive appointments, bringing the firm's headcount to 11. Anne Muir joins the firm as director of portfolio from the University of Dundee, where she was deputy director for research and innovation services and prev
Scottish cleantech bioscience firm Penrhos Bio has successfully secured a further £3 million in capital through its Series A funding round. The raise comes from a consortium of investors including St Andrews-based firm Eos, New York branding partner Earthbound Brands LLC, and Scotland’s
St Andrews-based impact investment firm Eos Advisory has secured a commitment of up to £10 million from British Business Investments, a commercial subsidiary of the British Business Bank. The investment, facilitated through the Regional Angels Programme, will be deployed alongside Eos’s
St Andrews-based impact investment firm Eos has added to its portfolio and team following a record year of activity in 2022. Investee companies are up to 18, with the latest investment in Edinburgh-headquartered robotic rehabilitation specialist Bioliberty during Q1.
Dxcover — a Glasgow-based company developing a blood test that can detect cancer at an early stage — has raised £9.7 million through a Series A investment round and grant funding. The £7.5m funding round was led by existing investors Eos Advisory LLP, Mercia Asset M
Scottish startup Waire Health has received £2 million in funding from St Andrews-based Eos Advisory and Scottish Enterprise. The investment will allow the firm to scale its sensor technology and grow its management team, production, and product development capabilities, while enablin
Green Bioactives Ltd (GBL), a Edinburgh-based firm dedicated to the discovery, development and sustainable production of high-value natural products derived from plant cell cultures, has successfully completed a £2.6 million seed financing round. The funding round was led by Eos Advisory LLP a
Cleantech start-up Penrhos Bio has secured a £1 million investment with the support of St Andrews-based impact investment firm Eos Advisory. The investment will accelerate the commercialisation of its patented platform technology, RemoraTM, developed in collaboration with Unilever, that protec
St Andrews-based investment firm Eos Advisory has strengthened its team, with Andrew Durkie joining as a partner, and Andy Lothian and Sandy Kennedy appointed as non-executive growth advisors. Andrew Durkie is a chartered accountant who brings over twenty years’ experience in mergers and
Edinburgh-based life sciences company Carcinotech, a MedTech specialist in the manufacture of 3D printed tumours developed from cancer stem cells, primary cells, and established cell lines, has secured a £1.6 million investment from leading Scotland-based investors to accelerate commercialisat